TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Washed Versus Standard Blood Cell Transfusions in Pediatric Open Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age \< 18 years~2. surgical repair at URMC by the pediatric cardiac surgical team~3. informed consent signed by the parent or legal guardian, and if applicable, assent obtained from the subject.~Exclusion Criteria:~1. Age ≥18 years~2. inability to provide consent/assent; 3) subjects having emergent surgical procedures. Subjects with chronic inflammatory or autoimmune disorders will not be excluded

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard leukoreduced irradiated blood cell transfusion group
- 2 (Type: EXPERIMENTAL): Washed leukoreduced irradiated blood cell transfusion group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Written informed consent must be obtained before any assessment is performed.~* Males and females ages 40 to 80 years~* Smoking history of at least 10 pack-years~* Diagnosis of COPD according to GOLD guidelines (GOLD, 2010), with a post-bronchodilator FEV¬1 \< 80% predicted and FEV1/FVC ratio \< 0.70~* BMI \<20 kg/m2 or skeletal muscle mass index by DXA \< 7.25 kg/m2 for men or \<5.45 kg/m2 for women.~* In general stable health, including managed COPD, by past medical history, physical examination, vital signs at baseline as determined by the investigator.~Exclusion criteria:~* Patients with MRC dyspnoea grade 5 (i.e. patients too breathless to leave the house or breathless when dressing)~* Plans for lung transplantation or lung reduction surgery within four months of enrollment~* Patients participating in a formal pulmonary rehabilitation program within 3 months of dosing~* History of malignancy of any organ system (other than excised non-melanomatous carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~* Diseases other than cancer known to cause cachexia or muscle atrophy, including but not limited to congestive heart failure of any stage, chronic kidney disease (estimated GFR \< 30 mL/min using the MDRD equation), rheumatoid arthritis, primary myopathy, stroke, HIV infection, tuberculosis or other chronic infection, uncontrolled diabetes mellitus, etc.~* Inflammatory bowel disease, celiac disease, short bowel syndrome, pancreatic insufficiency~* Use of any prescription drugs known to affect muscle mass, including androgen supplements, anti-androgens (such as LHRH agonists), anti-estrogens (tamoxifen, etc.) recombinant human growth hormone (rhGH), insulin, oral beta agonists, megestrol acetate, dronabinol, metformin, etc.~* Hemoglobin concentration below 11.0 g/dL at screening.~* Liver disease or liver injury.~* Use of other investigational drugs at the time of enrollment, or within 30 days and for any other limitation of participation in an investigational trial based on local regulations.~* Women of child-bearing potential.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- BYM338 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Foley OR MisO for the Management of Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All women 18 years of age or greater~* singleton gestation~* vertex presentation~* 37 weeks gestational age or greater~* undergoing an IOL~* bishop score less than or equal to 6~* cervical dilation less than or equal to 2cm~Exclusion Criteria:~* All women less than 18 years of age~* Contraindication for vaginal delivery~* Prior cesarean delivery~* Multiple gestation~* Intrauterine fetal demise~* Fetal anomaly~* HIV~* Unable to consent/ non-English speaking~* Non-reassuring fetal heart rate~* Patients with hemolysis elevated liver enzymes and low platelets~* Eclampsia~* Intrauterine growth restriction (IUGR) 5th percentile with abnormal dopplers~* IUGR less than 10th percentile with reversed end diastolic flow~* Recurrent late decelerations w~* Continuous contractions more than 3 times in 10 minutes at onset of IOL (given that this is a contraindication to misoprostol use at our institution)~* Bishop score is greater than 6~* Cervical dilation greater than or equal to 2cm~* Confirmed ruptured membranes

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cervical foley & Misoprostol (Type: EXPERIMENTAL): Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor.
- Misoprostol only (Type: EXPERIMENTAL): Patients randomized to this arm will receive misoprostol only to induce their labor.
- Cervical foley alone (Type: EXPERIMENTAL): Patients randomized to this arm will receive a cervical foley to induce their labor.
- Cervical foley & Pitocin (Type: EXPERIMENTAL): Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with D-IBS~* Aged 18-65 years~* No abdominal surgery (except appendectomy or cholecystectomy as long as patients IBS-diarrhea symptoms preceded the cholecystectomy~Exclusion Criteria:~* Participants with known chronic liver disease or Aspartate aminotransferase (AST) or Alanine transaminase (ALT) \> 2.0 X upper limit of normal~* Hypertriglyceridemia and pancreatitis by history~* Diabetes or hypoglycemia~* Significant coagulation disorder~* History of bowel obstruction~* Serum triglycerides \>500 mg/dL~* History of vitamin A, D, E, or K deficiencies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam (Type: EXPERIMENTAL): Participants received colesevelam 1.875 g twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Different Lipid Emulsions for Parenteral Nutrition in Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* prematurity (birth weight 500 - 1500 g)~* postnatal age \<= 72 h~* need for cumulative parenteral energy supply of at least 70% during study duration~* signed informed consent form~Exclusion Criteria:~* simultaneous participation in another clinical study~* platelet count below 50000 /ml~* cumulative enteral energy supply of \> 30 % during study duration~* serious congenital infections and/or diseases~* serious metabolic disturbances~* severe cranial bleeding (Papile III, IV)~* need for administration of blood products~* contra-indication for iv lipid administration~* withdrawal of consent

- Gender: ALL
- Minimum Age: 5 Hours
- Maximum Age: 3 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Lipidem 20 %
- 2 (Type: ACTIVE_COMPARATOR): Lipofundin MCT/LCT 20%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TYPE 2 HEPATORENAL SYNDROME

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Cirrhosis with ascites with serum creatinine more than 1.5 mg/dl and less than 2.5 mg/dl~2. Absence of shock, fluid losses and treatment with nephrotoxic drug~3. No improvement in renal function following diuretic withdrawal and plasma volume expansion~4. No ultrasound evidence of renal parenchymal disease or obstructive uropathy 5.Absence of proteinuria more than 500 mg/24 hour~Exclusion Criteria:~1. Patients with history of coronary artery disease~2. Cardiomyopathy~3. Ventricular arrhythmia~4. Obstructive arterial disease of limbs -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Terlipressin and Type-2 HRS (Type: ACTIVE_COMPARATOR): Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
- Noradrenaline and Type-2 HRS (Type: ACTIVE_COMPARATOR): Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CDI is confirmed by clinical symptoms (either \> 3 unformed bowel movements or ≥ 200ml of unformed stool (for subjects having rectal collection devices)) in the 24 hours prior to randomization and CDI test confirmed positive for presence of C. difficile toxin A or B in stool within 48 hr prior to randomization.~* Subject agrees not to participate in another interventional study whilst participating in this study.~Exclusion Criteria:~* Subject is taking or requiring to be treated with prohibited medications~* Subject has received more than one day of dosing of any therapy for CDI within the last 48 hours~* Subject has experienced more than 2 previous episodes of CDI in the 3 months prior to study enrolment~* Subject is unable to swallow oral study medication.~* Subject has a current diagnosis of toxic megacolon.~* Subject is not willing to adhere to the provisions of treatment and observation specified in the protocol.~* Subject has been randomized into this study previously, has taken any investigational drug within 28 days or 5 half lives, whichever is longer, prior to enrollment, or is currently participating in another clinical study which may influence the assessment of efficacy and/or safety endpoints of this study, in the opinion of the Sponsor.~* Subject has previously participated in a CDI vaccine study~* Subject has hypersensitivity to fidaxomicin, vancomycin or any of its components.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fidaxomicin Extended Pulsed Regimen (EPFX) (Type: EXPERIMENTAL): Participants receive 200 mg fidaxomicin from day 1 to day 5 twice daily, followed by a 1-day gap (day 6) before starting alternate day dosing of 1 tablet of fidaxomicin 200 mg once daily from day 7 to day 25.
- Vancomycin (Type: EXPERIMENTAL): Participants receive 125 mg vancomycin from day 1 to day 10, 4 times daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Female patients with histologically proven breast adenocarcinoma~* Presence of metastatic disease No more than 2 prior chemotherapy regimens for metastatic disease, which could include trastuzumab Patients must currently be on letrozole and developed acquired resistance as defined by disease progression on letrozole following previous response (partial response or better, stable disease superior or equal to 24 weeks)~Diagnosis of disease progression inferior or equal to 6 weeks prior to trial entrydefined as:~1. Increase in the number of bone lesions on bone scan or on MRI AND/OR~2. Increased pain in an area of known bony metastasis AND superior or equal to 2 serial elevations in CA 15.3 AND/OR~3. Progression according to RECIST criteria on CT scan, MRI, or x-ray Patients must have documented menopause confirmed by estradiol level inferior to 11 pg/ml~Exclusion criteria:~* Premenopausal patients~* Rapidly progressive disease in major organs (i.e. lymphangitic spread in the lung and/or bulky liver metastasis) Patient with brain metastasis Significant cardiovascular diseases Previous treatment with an EGFR and/or HER-2 inhibiting drug(patients who received trastuzumab with chemotherapy but not with letrozole can be enrolled)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BIBW 2992 (Type: EXPERIMENTAL): To study BIBW 2992 in association with letrozole in hormonoresistant metastatic breast cancer
- Letrozole (Type: OTHER): Hormonotherapy for metastatic breast cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dendritic Cell Vaccine for Patients With Brain Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
PATIENT ELIGIBILITY~Inclusion Criteria~1. Patients with newly diagnosed or recurrent glioma of WHO Grade III or IV {anaplastic astrocytoma (AA), anaplastic astro-oligodendroglioma (AO), or glioblastoma (GBM)} will be eligible for this protocol.~2. Patients must have had surgical resection at UCLA (University of California, Los Angeles), for which a separate informed consent was signed for the collection of their tumor prior to surgery.~3. After surgery, a pathological diagnosis of malignant glioma (WHO Grade III or IV) will need to be established.~4. Patients must be 18 years or older and able to read and understand the informed consent document. Patients must sign the informed consent indicating that they are aware of the investigational nature of this study.~5. Patients must have a Karnofsky performance status (KPS) rating of \> 60 prior to initiating treatment. Patients may be enrolled at a KPS of \< 60 if it is felt that the patient will have adequate opportunity to recover to a KPS of \> 60 by the initiation of treatment.~Exclusion Criteria~1. Subjects with an active infection.~2. Inability to obtain informed consent because of psychiatric or complicating medical problems.~3. Unstable or severe intercurrent medical or psychiatric conditions as determined by the Investigator.~4. Females of child-bearing potential who are pregnant or lactating or who are not using approved contraception.~5. History of immunodeficiency (e.g., HIV) or autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, vasculitis, polymyositis-dermatomyositis, scleroderma, multiple sclerosis, or juvenile-onset insulin-dependent diabetes) that may be exacerbated by immunotherapy.~6. Subjects with organ allografts.~7. Inability or unwillingness to return for required visits and follow-up exams.~8. Subjects who have an uncontrolled systemic malignancy that is not in remission.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tumor Lysate-pulsed DC vaccination (Type: EXPERIMENTAL): Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.
- Tumor lysate-pulsed DC vaccination+0.2% resiquimod. (Type: EXPERIMENTAL): Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.
- Tumor-lysate pulsed DC vaccination +adjuvant polyICLC. (Type: EXPERIMENTAL): Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alcohol & Mobile Phone Study to Reduce High-risk Alcohol Use and Consequences

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Typically drinking 2+ days/week, having at least 1 occasion of heavy episodic drinking (4+ women/5+ men) in last 2 weeks, having 4 or more negative consequences in the last month, owning a smartphone with a data package, agreeing to install the app on their phone and receive notifications.~* Student at a 2- or 4- year college where recruitment is located~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Mobile Alcohol Expectancy Intervention (Type: EXPERIMENTAL): Participants randomized to the intervention condition will receive twice daily intervention messages for three weeks and have access to other psycho-educational alcohol information.
- Assessment-only Control (Type: NO_INTERVENTION): Participants randomized to the control group will not receive any intervention. They will be an assessment-only control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Her pregnancy is confirmed at 16 to 24 weeks at their first booking.~* She is willing to participate and complete the test schedule, and has given informed consent.~* She is willing to have supervised delivered at maternity units in the district.~* She lives within the study district.~Exclusion Criteria:~* She has a past obstetric and medical history that will adversely affect the interpretation of outcomes such as repeated stillbirths and eclampsia.~* She has a haemoglobin level below 5.0 g/dl.~* She has malaria that is severe enough to require parenteral medication.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): OptiMAL® antigen screening and treatment with SP plus LLIN
- 2 (Type: EXPERIMENTAL): OptiMAL® antigen screening and treatment with AQ+AS plus LLIN
- 3 (Type: ACTIVE_COMPARATOR): SP-IPTp plus LLIN

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete